McLaren Cancer Institute Names New Leader

Dr. Justin Klamerus named interim president, medical director

FLINT, Mich.--(BUSINESS WIRE)--McLaren Health Care has selected Justin F. Klamerus, M.D., to guide McLaren Cancer Institute as its interim president and medical director.

“We’re proud to welcome Dr. Klamerus to McLaren Cancer Institute during this very exciting time”

Klamerus will transition into the position, replacing Dr. Ray Demers, who will retire March 31, 2013, after serving more than 10 years as president and medical director.

“We’re proud to welcome Dr. Klamerus to McLaren Cancer Institute during this very exciting time,” said Phil Incarnati, president and CEO of McLaren Health Care. “His strategic leadership and clinical expertise will add to the strong foundation already in place at McLaren Cancer Institute and will help us launch new initiatives to treat cancer patients, such as the McLaren Proton Therapy Center.”

Dr. Klamerus is a medical oncologist who most recently served as director of cancer services for McLaren Northern Michigan in Petoskey and medical director for the Oncology & Infusion Therapy Center at Otsego Memorial Hospital in Gaylord. Klamerus also has served as a principal investigator for McLaren Cancer Institute. He will continue to see patients in Northern Michigan.

“I look forward to building on the strengths of a network of talented professionals serving cancer patients in our system,” said Dr. Klamerus. “McLaren Cancer Institute is poised to make a real difference. With the construction of the new McLaren Proton Therapy Center, we will offer enhanced radiation therapy services available nowhere else in Michigan. McLaren’s commitment to fighting cancer couldn’t be more apparent.”

As interim president and medical director, Dr. Klamerus will provide leadership and direction to the medical and administrative staff. His responsibilities also include establishing and maintaining quality care standards and metrics, overseeing continued growth of the cancer clinical trials program and ensuring exceptional patient care throughout McLaren Cancer Institute.

Dr. Klamerus is a diplomate of the American Board of Internal Medicine and is board certified in medical oncology and internal medicine. He is a member of the American College of Physician Executives, and an associate to both the American Society of Clinical Oncology and the American College of Physicians. Dr. Klamerus has authored more than 10 publications or chapters and has been the principal researcher for more than a dozen active clinical protocols.

He attended Michigan State University’s College of Human Medicine and completed his internship and residency at Ohio State University and a fellowship in medical oncology at Johns Hopkins University. Dr. Klamerus will complete a Master of Medical Management from H. John Heinz III College at Carnegie Mellon University in February 2013.

About McLaren Cancer Institute

The McLaren Cancer Institute is a wholly owned subsidiary of the McLaren Health Care Corporation. Its premise is to facilitate the integration of evidence-based oncology research with state-of-the-art cancer treatment and deliver newly discovered treatment options to physicians and patients in communities throughout Michigan. By conducting important research and connecting researchers with local providers, we enhance existing knowledge of cancer and translate research findings to patient care more quickly. The nonprofit system includes cancer centers affiliated with community and regional hospitals of the McLaren Health Care system, including Bay Region, Central Michigan, Clarkston, Greater Lansing, Lapeer Region, Flint, Macomb, Northern Michigan and Oakland, as well as affiliate partnerships with Marquette General Health System and Memorial Cancer Center in Owosso.

About McLaren Health Care

With headquarters in Flint, Mich., McLaren Health Care is annually recognized as one of the top integrated health networks in the nation. McLaren is one of the largest health care providers in the state with a system that reaches more than half of Michigan residents through more than 200 locations, 17,400 employees and 11,000 network physicians. McLaren Health Care had net revenues of $2.5 billion in 2012 and has experienced double-digit growth each year since 1989. The nonprofit system includes medical centers in Bay City, Flint, Lapeer, Lansing, Mount Clemens, Mount Pleasant, Petoskey and Pontiac. Additional health care services are provided at McLaren Clarkston; McLaren Bay Special Care in Bay City; McLaren Orthopedic Hospital in Lansing; and McLaren Proton Therapy Center in Flint (beginning in 2013). McLaren Health Care also operates McLaren Medical Group, an employed physician network; McLaren Homecare Group, an award-winning home health, hospice and medical supplies provider; McLaren Health Plan, a licensed HMO offering benefit plans for commercial businesses and Medicaid recipients; and McLaren Cancer Institute, the largest cancer care network of its kind in the state. For more information, visit mclaren.org.